Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3063725 | 0.86 | DPP4 (0.48) | DPP4CYP3A4 | |
| SCHEMBL13139857 | 0.78 | DPP4 (0.56) | DPP4CYP3A4 | |
| SCHEMBL3059451 | 0.78 | DPP4 (0.56) | DPP4CYP3A4 | |
| SCHEMBL3071649 | 0.78 | DPP4 (0.46) | DPP4CYP3A4 | |
| SCHEMBL3069487 | 0.73 | DPP4 (0.45) | DPP4 | |
| SCHEMBL13139855 | 0.69 | DPP4 (0.57) | DPP4CYP3A4 | |
| SCHEMBL3075383 | 0.69 | DPP4 (0.57) | DPP4CYP3A4 | |
| SCHEMBL3064302 | 0.69 | DPP4 (0.50) | DPP4CYP3A4 | |
| SCHEMBL13139852 | 0.69 | DPP4 (0.50) | DPP4CYP3A4 | |
| SCHEMBL4667772 | 0.67 | DPP4 (0.53) | DPP4CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1699777-B1 | DIPEPTIDYL PEPTIDASE INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2012-12-12 | — | — | EP | claimed |
| US-7790734-B2 | Dipeptidyl peptidase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-07 | — | — | US | claimed |
| JP-2007505121-A | — | — | 2007-03-08 | — | — | JP | claimed |
| EP-1699777-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2006-09-13 | — | — | EP | claimed |
| WO-2005026148-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2005-03-24 | — | — | WO | claimed |
| US-20050065145-A1 | Dipeptidyl peptidase inhibitors | SYRRX, INC. | 2005-03-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065145-A1 | Dipeptidyl peptidase inhibitors | DPP4, DPP3, DPP7 | DPP4 1/4885CYP3A4 194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.